Találati lista | Tudóstér

001-es BibID:	BIBFORM136431
Első szerző:	Antal-Szalmás Péter (laboratóriumi szakorvos)
Cím:	Autoantibodies in the diagnostics, prognostics and follow-up of primary biliary cholangitis / Antal-Szalmás Péter, Bencze Dóra, Demeter Sarolta, Pénzes-Daku Krisztina, Szabó Lilla, Tóth Beáta, Földesi Róza, Papp Mária, Nagy Gábor
Dátum:	2026
ISSN:	2589-9090
Megjegyzések:	Primary biliary cholangitis (PBC), is a chronic autoimmune liver disease, characterized by cholangiopathy, cholestasis and in the long-term fibrosis, biliary cirrhosis and ultimately end-stage liver disease unless liver transplantation is applied. The diagnostics of PBC is based on biochemical tests, autoantibody measurements and liver histopathology. Abdominal ultrasound, later magnetic resonance cholangiopancreatography (MRCP) or endoscopic ultrasound can be effective methods for imaging the intra- and extrahepatic bile ducts. Concerning autoantibodies, anti-mitochondrial (AMA) and PBC-specific antinuclear antibodies (ANA) are the front-line tests that can be identified by indirect immunofluorescence tests or solid-phase immunoassays. AMA and especially the AMA-M2 variant have a high sensitivity and specificity for PBC, while anti-gp210 and anti-sp100 (PBC-specific ANAs) have a lower sensitivity but very high specificity for the disease. Anti-centromere antibodies (ACA) can help in the diagnostics of PBC and some overlap syndromes. Novel emerging markers ? anti-hexokinase 1 and anti-Kelch-like 12 protein (anti-KLHL12) ? can help the identification of rare AMA- and ANA-negative PBC cases. There is cumulating evidence that beside diagnostics certain autoantibodies can provide information about the prognostics of PBC, can predict therapy response, furthermore, can act as activity marker in follow-up of the patients during therapy. We summarize here the most important data about the accepted and potential clinical applications of traditional and emerging new autoantibodies in PBC.
Tárgyszavak:	Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban folyóiratcikk autoimmune liver disease primary biliary cholangitis anti-mitochondrial antibody anti-gp210 anti-sp100 anti-HK1 anti-KLHL-12
Megjelenés:	Journal of Translational Autoimmunity. - 12 (2026), p. 1-15. -
További szerzők:	Bencze Dóra (1992-) Demeter Sarolta (1987-) (orvos) Pénzes-Daku Krisztina (1978-) (biológus) Szabó Lilla (1993-) (molekuláris biológus) Lajszné Tóth Beáta (1978-) (molekuláris biológus) Földesi Róza (1967-) (klinikai laboratóriumi kutató, PhD hallgató) Papp Mária (1975-) (belgyógyász, gasztroenterológus) Nagy Gábor (1974-) (laboratóriumi szakorvos, laboratóriumi hematológus és immunológus)
Internet cím:	Szerző által megadott URL DOI Intézményi repozitóriumban (DEA) tárolt változat
Borító:
Saját polcon:

001-es BibID:	BIBFORM136591
Első szerző:	Nagy Gábor (laboratóriumi szakorvos, laboratóriumi hematológus és immunológus)
Cím:	Autoantibodies in the follow-up of autoimmune hepatitis / Nagy Gábor, Bencze Dóra, Demeter Sarolta, Pénzes-Daku Krisztina, Szabó Lilla, Tóth Beáta, Földesi Róza, Papp Mária, Antal-Szalmás Péter
Dátum:	2026
ISSN:	2589-9090
Megjegyzések:	Autoimmune hepatitis (AIH) is a rare, chronic, immune mediated liver disorder with unknown origin, associated with elevation of serum transaminases and IgG, positivity of certain autoantibodies and characteristic histopathological alterations in the liver. The clinical scenario is variable, the disease can be asymptomatic for a long time, noticed accidently by liver enzyme elevation or diagnosed only when liver cirrhosis has already developed. In rare cases acute hepatitis with liver failure is the starting event. In general, immunosuppressive treatment is required to diminish the progression of liver destruction and to prevent liver transplantation. The most important autoantibodies involved in AIH diagnostics ? antinuclear antibodies, smooth muscle antibodies, anti?liver kidney microsomal type 1, anti-liver cytosolic antigen 1 or anti?soluble liver antigen ? can be used for definition of AIH subtypes, too. These parameters are included in current AIH diagnostic guidelines. Since the fate of the patients depends very much on the proper choice and efficacy of the applied therapy prognostic and predictive markers of disease outcome can be essential in initiating therapy, while markers of disease activity and therapy response can support follow-up. Some biochemical parameters or histopathological data can be used for these purposes, but the potential role of AIH-specific autoantibodies in these is not entirely clear. In this current review the potential use of classical and emerging autoantibodies in diagnostics, prognostics, and follow-up of AIH patients will be discussed.
Tárgyszavak:	Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban folyóiratcikk Autoimmune liver disease Autoimmune hepatitis Antinuclear antibodies (ANA) Smooth muscle antibodies (SMA) Anti-liver kidney microsomal type 1 antibodies (anti-LKM1) Anti-soluble liver antigen/liver pancreas antibodies (anti-SLA/LP)
Megjelenés:	Journal of Translational Autoimmunity. - 12 (2026), p. 1-12. -
További szerzők:	Bencze Dóra (1992-) Demeter Sarolta (1987-) (orvos) Pénzes-Daku Krisztina (1978-) (biológus) Szabó Lilla (1993-) (molekuláris biológus) Lajszné Tóth Beáta (1978-) (molekuláris biológus) Földesi Róza (1967-) (klinikai laboratóriumi kutató, PhD hallgató) Papp Mária (1975-) (belgyógyász, gasztroenterológus) Antal-Szalmás Péter (1968-) (laboratóriumi szakorvos)
Internet cím:	Szerző által megadott URL DOI Intézményi repozitóriumban (DEA) tárolt változat
Borító:
Saját polcon:

001-es BibID:	BIBFORM006180
Első szerző:	Szekanecz Éva (onkológus szakorvos)
Cím:	Tumor-associated antigens in systemic sclerosis and systemic lupus erythematosus : associations with organ manifestations, immunolaboratory markers and disease activity indices / Éva Szekanecz, Gabriella Szűcs, Zoltán Szekanecz, Tünde Tarr, Péter Antal-Szalmás, Szilvia Szamosi, János Szántó, Emese Kiss
Dátum:	2008
Megjegyzések:	Some tumor-associated antigens (TAAs) are expressed on inflammatory cells. We previously detected increased production of CA15-3, CA19-9 and CA125 in rheumatoid arthritis (RA). The production of some TAAs may also be increased in patients with systemic sclerosis (SSc), systemic lupus erythematosus (SLE) and other connective tissue diseases. Some of these TAAs contain sialylated carbohydrate motifs and they are involved in tumor-associated cell adhesion and metastasis. OBJECTIVES: We assessed levels of TAAs in the sera of SSc, SLE patients, patients with infectious diseases and healthy subjects. Serum TAA levels were correlated with each other, as well as with disease activity markers and organ involvement. METHODS: TAAs including CEA, CA15-3, CA72-4, CA125 and CA19-9 were assessed by immunoassay in the sera of 92 patients with SSc, 40 patients with SLE, 50 age- and sex-matched healthy controls, as well as with 40 patients with current bacterial or viral infections. Normal upper limits for these TAAs were 3.4 mg/l, 25 kU/l, 6.9 kU/l, 35 kU/l and 34 kU/l, respectively. RESULTS: There were significantly more SSc patients showing abnormally high levels of CA19-9 (8.8% vs 2.0%), CA125 (11.0% vs 6.0%) and CA15-3 (28.4% vs 14.0%) in comparison to controls (p < 0.05). In SLE, significantly more patients had elevated levels of CEA (32.5% vs 20.0%), CA19-9 (7.5% vs 2.0%), CA125 (15.0% vs 6.0%) and CA72-4 (15.0% vs 8.0%) than did controls (p < 0.05). The mean absolute serum levels of CEA (6.6+/-1.7 vs 1.8+/-1.4 mg/l) and CA15-3 (22.9 +/- 1.8 vs 18.6 +/- 2.2 kU/l) were also significantly higher in SSc compared to controls (p < 0.05). We found numerous correlations between the serum levels of different TAAs within the SSc and SLE population. Among SSc patients, serum CEA (R = 0.290; p = 0.005), CA15-3 (R = 0.260; p = 0.020) and CA19-9 (R = 0.257; p = 0.013) correlated with renal involvement. Serum CA15-3 also correlated with joint involvement (R = 0.329; p = 0.003), ANA positivity (R = 0.288; p = 0.010) and CRP levels (R = 0.407; p < 0.001). Within the SLE population, serum CA72-4 correlated with central nervous involvement (R = 0.624; p = 0.004) and CA125 correlated with the SLEDAI composite activity index (R = 0.666; p = 0.002). Patients with infections exerted serum TAA patterns similar to healthy controls. CONCLUSION: The concentration of some TAAs may be elevated in the sera of patients with SSc or SLE in comparison to healthy subjects. Pathogenically, most of these TAAs contain carbohydrate motifs and thus they may be involved in inflammation-associated adhesive events. Furthermore, the production of some TAAs may correlate with organ involvement or disease activity in scleroderma or lupus.
Tárgyszavak:	Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
Megjelenés:	Journal of Autoimmunity. - 31 : 4 (2008), p. 372-376. -
További szerzők:	Szűcs Gabriella (1963-) (belgyógyász, allergológus és klinikai immunológus, reumatológus) Szekanecz Zoltán (1964-) (reumatológus, belgyógyász, immunológus) Tarr Tünde (1976-) (belgyógyász, allergológus és klinikai immunológus) Antal-Szalmás Péter (1968-) (laboratóriumi szakorvos) Szamosi Szilvia (1975-) (belgyógyász, reumatológus) Szántó János (1949-2024) (onkológus szakorvos) Kiss Emese (1960-) (belgyógyász, immunológus)
Internet cím:	elektronikus változat DOI
Borító:
Saját polcon: